BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 14, 2009
View Archived Issues
Matrix Metalloproteinase Does About-Face in Melanoma Study
Read More
NewCo News: GliaMed Gets a Facelift as it Moves into Wound Healing
Read More
Record-High Side Effects Reported to FDA in 2008
Read More
Other News To Note
Read More
Appointments And Advancements
Read More
FDA Reviews Solzira; XenoPort Exercises Co-Promote Option
While the FDA reviews a new drug application for Solzira (gabapentin enacarbil) in restless legs syndrome, XenoPort Inc. exercised its option to co-promote the drug in the U.S. with partner GlaxoSmithKline plc. (BioWorld Today)
Read More
Cell Therapeutics Raises $15M for its Late-Stage Development
Read More